Patents by Inventor Alistair J. Leigh
Alistair J. Leigh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150196494Abstract: The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active, metal salts. The core of the tablet is a substantially dry powder comprising about 10 to 60 wt % picoplatin wherein the picoplatin is a particulate of less than about 10 microns average particle diameter, about 40-80 wt % of a filler comprising a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate, and an effective amount of up to about 5 wt % of a lubricant. The dosage form can further include a dispersant.Type: ApplicationFiled: March 25, 2015Publication date: July 16, 2015Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Ernest S.Y. Wong, Christen M. Giandomenico
-
Publication number: 20130202690Abstract: The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant.Type: ApplicationFiled: September 27, 2012Publication date: August 8, 2013Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Angelica F. Phillips, Hazel B. Breitz
-
Publication number: 20130183433Abstract: The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox- active metal salts. The core of the tablet is a substantially dry powder comprising about 10 to 60 wt % picoplatin wherein the pieoplatin is a particulate of less than about 10 microns average particle diameter, about 40-80 wt % of a filler comprising a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate, and an effective amount of up to about 5 wt % of a lubricant. The dosage form can further include a dispersant.Type: ApplicationFiled: August 16, 2012Publication date: July 18, 2013Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Ernest S.Y. Wong, Christen M. Giandomenico
-
Publication number: 20120123121Abstract: An improved method for the synthesis of the anticancer drug picoplatin is provided. Condensation of a tetrachloroplatinate salt (TCP), such as potassium tetrachloroplatinate, and 2-picoline, in a solvent, is catalyzed by the presence of oxygen, such as in air, and additionally catalyzed by the presence of a Pt+4 complex, such as potassium hexachloroplatinate. The oxygen can be introduced into the reaction mixture by sparging, optionally with high shear mixing and under an inert gas headspace. The product trichloropicolineplatinate salt (TCPP) is a key intermediate in the synthesis of picoplatin, to which it can be converted by reaction of the TCPP with ammonia.Type: ApplicationFiled: June 11, 2010Publication date: May 17, 2012Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Steffen Jost
-
Publication number: 20110033528Abstract: The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active metal salts. The core of the tablet is a substantially dry powder comprising about 10 to 60 wt % picoplatin wherein the picoplatin is a particulate of less than about 10 microns average particle diameter, about 40-80 wt % of a filler comprising a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate, and an effective amount of up to about 5 wt % of a lubricant. The dosage form can further include a dispersant.Type: ApplicationFiled: August 5, 2009Publication date: February 10, 2011Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Ernest S.Y. Wong, Christen M. Giandomenico
-
Publication number: 20100215727Abstract: Methods for stabilizing aqueous solutions of picoplatin are provided. Such stable, preferably aseptic solutions are particularly useful for preparing unit dosages of picoplatin for oral or intravenous administration, preferably in combination with at least one additional non-platinum anti-cancer agent.Type: ApplicationFiled: December 10, 2009Publication date: August 26, 2010Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Ronald A. Martell, David A. Karlin, Cheni Kwok, Christopher A. Procyshyn, Hazel B. Breitz, Paul L. Weiden
-
Publication number: 20100062056Abstract: The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant.Type: ApplicationFiled: August 5, 2009Publication date: March 11, 2010Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Angelica Phillips, Hazel B. Breitz
-
Patent number: 6100271Abstract: Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:CORE MOIETY --(R).sub.jwherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.Type: GrantFiled: June 7, 1995Date of Patent: August 8, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Alistair J. Leigh, Gail E. Underiner, Anil M. Kumar
-
Patent number: 6043250Abstract: Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:CORE MOIETY --(R).sub.jwherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.Type: GrantFiled: June 7, 1995Date of Patent: March 28, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Alistair J. Leigh, Gail E. Underiner, Anil M. Kumar, Glenn C. Rice
-
Patent number: 6020337Abstract: Therapeutic compounds, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, having a formula: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, halo, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, wherein the substituents of substituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl are other than halo; n is an integer from one to sixteen; R.sub.1, R.sub.2, and R.sub.3 are independently selected from the group consisting of a halo; haloacetoxy; hydrogen; hydroxy; oxo; --N.dbd.C.dbd.S; --N.dbd.C.dbd.O; --0--C.tbd.N; --C.tbd.N; --N.dbd.N.dbd.N; and --C--(R.sub.5).sub.3, R.sub.5 being independently a halo or hydrogen, at least one R.sub.5 being halo, at least one of R.sub.1, R.sub.2, and R.sub.3 being halo, cyano, isocyano, isothiocyano, azide or haloacetoxy group; R.sub.4 is hydrogen, C.sub.(1-6) alkyl, C.sub.(1-6) alkenyl, cyclo C.sub.Type: GrantFiled: September 16, 1997Date of Patent: February 1, 2000Assignee: Cell Therapeutics, Inc.Inventors: Alistair J. Leigh, John Michnick, Anil M. Kumar, J. Peter Klein, Gail Underiner
-
Patent number: 5889011Abstract: Compounds and pharmaceutical compositions thereof comprise the formula:(R)j- (core moiety),including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.Type: GrantFiled: June 27, 1997Date of Patent: March 30, 1999Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Alistair J. Leigh
-
Patent number: 5817662Abstract: Compounds and pharmaceutical compositions thereof comprise the formula:(R)j-(core moiety),including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.Type: GrantFiled: June 6, 1995Date of Patent: October 6, 1998Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Alistair J. Leigh
-
Patent number: 5807862Abstract: Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:CORE MOIETY--(R).sub.jwherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.Type: GrantFiled: June 7, 1995Date of Patent: September 15, 1998Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Alistair J. Leigh, Gail E. Underiner, Anil M. Kumar
-
Patent number: 5629423Abstract: A process for synthesizing enantiomerically pure chiral secondary alcohol compounds linked to a heterocyclic core moiety, using a natural chiral molecule starting material. The inventive process is particularly useful for bulk manufacturing of chiral secondary alcohol compounds.Type: GrantFiled: May 23, 1995Date of Patent: May 13, 1997Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Alistair J. Leigh, John Michnick, Anil M. Kumar, Gail E. Underiner